United States Patent 4,808,716 Landscape: Scope, Claim Construction, and Competitor Risk for 9-(phosphonylmethoxyalkyl)adenine Nucleoside Analogues
US Patent 4,808,716 claims a narrow class of 9-(phosphonylmethoxyalkyl)adenine compounds defined by (i) an adenine core substituted at the 9-position, (ii) a phosphonylmethoxyalkyl linker where the “alkyl” portion R2 is limited to enumerated chain/linker options, (iii) a limited set of substituents at the phosphonate-linked methoxyalkyl fragment via R1 (Claim 1: R1 = hydrogen; Claim 2: R1 = methyl or hydroxymethyl), and (iv) salts with alkali metals or ammonia. Commercial and litigation risk concentrates on knock-on products that use the same adenine substitution pattern and identical linker enumeration, especially where applicants cannot demonstrate a non-infringing linker choice or a non-covered salt form.
H1: US Patent 4,808,716 Scope and Claims for 9-(phosphonylmethoxyalkyl)adenine Phosphonate Nucleoside Analogues
What does US 4,808,716 claim, in plain claim terms?
Core coverage: 9-(phosphonylmethoxyalkyl)adenine compounds and their alkali-ammonia salts, with the only meaningful structural degrees of freedom being:
- the substituent at R1 (Claim 1: hydrogen; Claim 2: methyl or hydroxymethyl), and
- the specific linker identity enumerated as R2.
Claim 1 coverage (R1 fixed):
- Adenine substituted with “phosphonylmethoxyalkyl” at the 9-position.
- R1 is hydrogen.
- R2 is one of:
- methylene
- ethylene
- propylene
- ethylidene
- 1,2-O-isopropylidene-1,2-dihydroxypropylene
- Also covers corresponding salts with alkali metals or ammonia.
Claim 2 coverage (R1 variable):
- Adenine substituted with “phosphonylmethoxyalkyl” at the 9-position.
- R1 is one of:
- R2 is one of:
- methylene
- ethylene
- propylene
- ethylidene
- methoxyethylene
- benzyloxyethylene
- tetrahydropyranyl-2-oxyethylene
- (1-ethoxyethoxy)ethylene
- 1,2-O-isopropylidene-1,2-dihydroxypropylene
- Also covers salts with alkali metals or ammonia.
Practical infringement hook: If a competitor’s compound can be mapped onto the defined adenine-phosphonate-methoxyalkyl architecture and uses an R2 that matches any listed linker option, the claim is generally “on rails.” The main design-around levers are changing the linker so R2 no longer matches an enumerated item or using a non-salt form outside “alkali metals or ammonia.”
What are the key claim limitations in US 4,808,716 that define infringement?
Featured snippet answer: US 4,808,716 is limited to 9-(phosphonylmethoxyalkyl)adenine where R1 equals hydrogen (Claim 1) or methyl/hydroxymethyl (Claim 2), and R2 equals one of the enumerated linker types, with coverage extending to salts with alkali metals or ammonia.
Which structural element is the patent’s “center of gravity”?
The patent’s anchor is the adenine ring substituted at the 9-position with a phosphonylmethoxyalkyl substituent. This is not a general “adenine phosphonate” claim; it is keyed to the phosphonylmethoxyalkyl linkage described in the patent’s formulae (I and the formula under Claim 2).
How do R1 and R2 operate as “claim gates”?
- R1 gate: distinguishes two families.
- Claim 1: R1 is hydrogen.
- Claim 2: R1 is methyl or hydroxymethyl.
- R2 gate: enumerates specific linker identities.
- If R2 is one of the listed structures, that branch is potentially captured.
- If R2 is a novel linker not listed, a non-infringement argument is typically strongest on the literal “selected from” limitation.
Does “salts thereof” broaden coverage materially?
It can broaden practical coverage but only within the specified salt types:
- covered salts: alkali metals and ammonia salts.
- likely non-covered salts: salts not within those categories (for example, many amines, acids, or quaternary ammonium counterions) unless another claim elsewhere covers them.
How strong is the literal scope: what does “R2 is selected from the group consisting of …” do?
Featured snippet answer: The “group consisting of” language makes the R2 limitation effectively closed. That narrows literal infringement to compounds where the linker matches one of the listed R2 structures.
Closed set effect on design-around
Because the claim uses “selected from the group consisting of” enumerated items, competitors generally mitigate infringement by:
- choosing an R2 linker that is structurally distinct from every enumerated option, or
- using a protecting group or substitution pattern that changes the linker identity such that it is no longer one of the listed R2 members.
Likely interpretation focus points
In practice, claim construction disputes for such patents often reduce to:
- whether a proposed linker is truly the enumerated structure (for example, whether a given substituent pattern is “methoxyethylene” versus a different substituted ethylene ether),
- how the patent describes the phosphonate-linked methoxyalkyl chain in formula terms,
- whether the competitor’s compound falls under the same R1 variant (hydrogen vs methyl/hydroxymethyl).
What do Claim 1 vs Claim 2 cover, and how do they overlap?
Featured snippet answer: Claim 1 covers R1 = hydrogen with a five-item R2 list; Claim 2 covers R1 = methyl or hydroxymethyl with a larger nine-item R2 list, including several additional ether-protected ethylene linkers.
Overlap map (R2 commonality)
Common R2 entries appearing in both claims:
- methylene
- ethylene
- propylene
- ethylidene
- 1,2-O-isopropylidene-1,2-dihydroxypropylene
Claim 2 adds additional R2 entries:
- methoxyethylene
- benzyloxyethylene
- tetrahydropyranyl-2-oxyethylene
- (1-ethoxyethoxy)ethylene
Business implication
If a competitor’s series uses protected ethylene linkers that correspond to Claim 2’s added R2 set, it expands capture. If the competitor uses only the base (unprotected or the shared R2 options), the product may align with Claim 1 (if R1 is hydrogen) or Claim 2 (if R1 is methyl or hydroxymethyl).
What formulations are covered by US 4,808,716?
US 4,808,716 as provided is directed to compounds and their salts. The claims excerpt does not include:
- pharmaceutical composition claims,
- dosage form claims,
- prodrug claims defined by specific formulation components,
- manufacturing-process claims.
So the scope for “formulations” is functionally limited to the salt identity (alkali metal or ammonia salts) rather than broad composition coverage.
Salt-form strategy risk
Because only certain salt types are named, competitors can reduce risk by using counterions not within “alkali metals or ammonia,” unless the patent contains additional claims covering those salts (not shown in the excerpt).
Does US 4,808,716 cover method-of-use or only compound structures?
Based on the claims provided, the patent is a chemical compound patent:
- it defines chemical structures,
- it does not define any therapeutic method-of-use limitation.
If other dependent claims exist (not shown), they could add utility or dosage limitations, but the excerpt only shows compound claims.
What patent landscape surrounds US 4,808,716 for nucleoside phosphonate analogues?
A complete landscape requires bibliographic and family data (continuations, related priority applications, and later patents citing or being cited). The provided prompt only includes two independent claim excerpts and no title/assignee/filing dates, so a full landscape cannot be produced from the available information.
What can be concluded from claim breadth alone
Even without family data, the breadth is inferable:
- The patent is narrowly defined to a specific structural genus.
- It is not an open-ended “all phosphonate prodrugs” claim; it is limited by R1 and R2 enumeration.
- It likely sits in a landscape with multiple analog patents for neighboring linker/protecting-group variants, because Claim 2 already expands the R2 set via additional ether-protected ethylene types.
When does US 4,808,716 lose exclusivity?
No filing date, priority date, term adjustment, or patent term extension information is provided. Without these, the exclusivity timeline cannot be computed or asserted.
How would an FDA generic challenge or biosimilar program intersect with US 4,808,716?
This is a small-molecule-like claim set (adenine phosphonylmethoxyalkyl), but no reference product, FDA NDA/ANDA, or listed Orange Book entries are provided. Without the drug link, no Paragraph IV or 505(b)(2)/505(j) risk can be mapped.
What is the practical claim strength: can competitors design around by changing R2?
Featured snippet answer: The most straightforward design-around is changing R2 to a structure not listed in either claim’s enumerated set. Because R2 is “selected from” a closed list, a non-listed linker can avoid literal infringement.
Likely non-infringement arguments
- R2 is not one of the enumerated members.
- R1 is not the enumerated substituent (Claim 1 hydrogen; Claim 2 methyl/hydroxymethyl).
- The product is not an alkali metal or ammonia salt covered by the salt portion.
Typical litigation leverage
When a patent uses closed-form structure selection (“consisting of”), infringement disputes usually focus on chemical equivalence and claim construction around what the enumerated linker “is” in structural terms, not on broad doctrine-of-equivalents arguments that expand beyond enumeration.
Which competitor categories face the highest risk from US 4,808,716?
Highest risk category: companies developing adenine phosphonate nucleoside analogs where the linker and substitution patterns match the enumerated R1/R2 sets and where the marketed active is delivered as an alkali metal or ammonia salt.
Lower risk category: molecules that are:
- adenine phosphonates but with a different linker architecture not matching any enumerated R2 option, or
- delivered as salts using counterions outside alkali metals/ammonia (assuming no other claims cover them).
Key Takeaways
- US 4,808,716 covers 9-(phosphonylmethoxyalkyl)adenine compounds defined by closed enumerations of R1 and R2 plus alkali metal/ammonia salts.
- Claim 1 is limited to R1 = hydrogen and a five-item R2 list.
- Claim 2 captures R1 = methyl or hydroxymethyl and expands R2 with additional ether-protected ethylene linkers.
- The “selected from the group consisting of” language makes R2 a primary literal infringement gate and a prime design-around lever.
- The excerpt provided does not include enough bibliographic or FDA linkage data to compute exclusivity timelines or map Orange Book and Paragraph IV risk.
FAQs
-
How do R1 values in US 4,808,716 affect infringement risk?
Claim 1 requires R1 = hydrogen; Claim 2 requires R1 = methyl or hydroxymethyl.
-
Is the R2 linker limitation in US 4,808,716 open-ended or closed?
It is closed by “selected from the group consisting of,” limiting literal coverage to the listed R2 structures.
-
Do alkali metal and ammonia salts broaden coverage in practice?
Yes, but only for salts with alkali metals or ammonia as specified in the claims.
-
Does US 4,808,716 claim therapeutic methods or only compounds?
The provided claims are compound claims; no method-of-use is shown.
-
What is the most direct design-around for US 4,808,716?
Change the linker so it no longer matches any enumerated R2 member, and/or use a salt type outside alkali metals/ammonia.
References
- United States Patent 4,808,716 (claims provided in prompt).
